CM  Vol.1 No.2 , September 2010
Prevalence of Glucose-6-Phosphate Dhydrogenase Deficient Neonates and Cost Effective of Enzyme Screening in Tehran, Iran
Abstract: Background: Newborn screening is an area with potential for immense impact in lifelong morbidity and mortality. Objective: To determine cost effective for glucose-6-phosphate dehydrogenase (G-6-PD) enzyme screening and prevalence of deficiency in newborns and children in Tehran, Iran. Materials and Methods: All full term newborns, neonates with icterus and children with acute hemolysis were evaluated to determine prevalence of G-6-PD enzyme deficiency and cost effectiveness of a screening test for G-6-PD enzyme deficiency. The qualitative color reduction test performed on healthy newborns and quantitative test on newborns with icterus and children with acute hemolysis. Results: Three (2%) of 146 screened newborns were G-6-PD deficient at a cost of $ 18 for three positive screening tests and $ 856 for 143 unaffected newborns Thirty-one (11.4%) of 272 newborns readmitted with icterus were G-6-PD deficient with a cost of 31 tests were $186 and $1446 for unaffected newborns. The only significant difference between G-6-PD deficient and normal newborns was bilirubin level (p < 0.001). Eleven (0.2%) of 5054 hospitalized children were found to be G-6-PD deficient at a screening cost of $ 66 and $ 3.258 for remainder children. The prevalence of G-6-PD is estimated to be approximately 2.4% and 2.2% in males and females respectively. Conclusion: Glucose-6- phosphate dehydrogenase screening in newborns is not cost effective and for prevention of hemolysis during the next years all newborns admitted with icterus should be evaluated for G-6-PD enzyme deficiency.
Cite this paper: nullH. Dahifar, A. Ghorbani and M. Ghods, "Prevalence of Glucose-6-Phosphate Dhydrogenase Deficient Neonates and Cost Effective of Enzyme Screening in Tehran, Iran," Chinese Medicine, Vol. 1 No. 2, 2010, pp. 55-57. doi: 10.4236/cm.2010.12011.

[1]   A. A. Fanarof and R. J. Martin, “Neonatal-Perinatal Medicine Disease of the fetus and infant,” 5th Edition, Mosby, USA, 1992.

[2]   A. Larsson, “Neonatal Screening for Metabolic, Endocrine, Infectious and Genetic Disorders,” Clinic in Perinatology, 2001, Vol. 28, No. 2, pp. 449-461.

[3]   WHO Working Group, “Glucose-6-Phosphate Dehydrogenase Deficiency,” Bulletin of the Health Organization, Vol. 67, 1989, pp. 601-611.

[4]   B. K. Burton, “Inherited metabolic disorders,” In: G. B. Avery, M. A. Fletcher and M. G. MacDonald, Neonatology, Pathophysiology and Management of the Newborn, 5th Edition, Lippincott Williams and Wilkins, USA, 1999, pp. 821-837.

[5]   M. Kaplan and C. Hammerman, “Glucose-6-Phosphate Dehydrogenase-Deficient Neonates: A Potential Cause for Concern in North America,” Pediatrics, Vol. 106, No. 6, 2000, pp. 1478-1480.

[6]   M. Kaplan, E. Beutler, H. J. Vreman, C. Hammerman, E. Levy-Lahad, P. Renbaum, et al., “Neonatal Hyperbiliru- Binemia in Glucose-6-Phosphate Dehydrogenase Deficient Heterozygotes,” Pediatrics, Vol. 104, No. 1, Part 1, 1999, pp. 68-74.

[7]   M. G. McDonald, “Hidden Risks: Early Discharge and Bilirubin Toxicity Due to Glucose-6-Phosphate Dehydrogenase Deficiency,” Pediatrics, Vol. 96, No. 4, Part 1, 1995, pp. 734-738.

[8]   H. Dahifar, A. Ghorbani and M. Ghods, “Isolated and Non-Isolated Enteric Pathogens in Children with Diarrhea and Related Laboratory Characteristics,” MHIRI, Vol. 22, 2008, pp. 40-46.